Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease modifying antirheumatic drugs: results from the BIOBADASER III registry.
OBJECTIVES: To assess the risk of cancer in patients with rheumatoid arthritis (RA) treated with biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). METHODS: We analyzed RA patients from the BIOBADASER III registry, a multicentre national registry of b/tsDMARDs, inclu...
| Autores: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2026 |
| País: | España |
| Recursos: | Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL) |
| Repositorio: | r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante |
| OAI Identifier: | oai:isabial.fundanetsuite.com:p11462 |
| Acesso em linha: | https://isabial.portalinvestigacion.com/publicaciones11462 https://doi.org/10.1093/rheumatology/keaf556 |
| Access Level: | acceso abierto |
| Palavra-chave: | DMARDs biologics cancer epidemiology registries rheumatoid arthritis targeted therapies |
| Resumo: | OBJECTIVES: To assess the risk of cancer in patients with rheumatoid arthritis (RA) treated with biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). METHODS: We analyzed RA patients from the BIOBADASER III registry, a multicentre national registry of b/tsDMARDs, included from 2000 to 2023. Patients with a history of cancer were excluded. Incidence rates (IRs) were analysed, and adjusted Cox regression models were used to estimate hazard ratios (HRs) for all cancers excluding non-melanoma skin cancer (NMSC), as well as for NMSC. Tumor necrosis factor inhibitors (TNFi) served as the reference for comparison. RESULTS: Among 4,635 RA patients (mean age 55.5 years; 79% female; median follow-up 3.6 years), 187 incident cancers were identified. For all cancers excluding NMSC, adjusted HRs (95% CI) compared with TNFi were: 1.2 (0.8-1.6) for IL6i, 0.9 (0.5-1.4) for CD20i, 1.2 (0.8-1.8) for JAKi, and 1.1 (0.8-1.6) for CTLA4-A. For NMSC, adjusted HRs (95% CI) were 0.6 (0.2-1.5) for IL6i, 0.6 (0.2-1.8) for CD20i, 0.7 (0.2-2) for JAKi, and 1.1 (0.5-2.6) for CTLA4-A. No increased cancer risk was observed when adjusting for cardiovascular risk or treatment line, for either cancer type. CONCLUSIONS: In this large, real-world cohort of RA patients, we found no increased cancer risk associated with any bDMARDs or tsDMARDs compared with TNFi. |
|---|